Aurobindo Pharma Limited — Q1 FY25
Aurobindo Pharma reported a solid Q1 FY25 with revenue of INR 7,567 crore (+10% YoY) and PAT of INR 919 crore (+61% YoY), driven by strong performance in Europe (EUR 221 million...
bullish
medium
✓ Verified against BSE filing
Indian management teams deliver on roughly 12% of specific earnings-call promises. A low score does not indicate dishonesty — it reflects how aspirational forward guidance typically is.
Q4 FY24
Eugia global revenue run rate of $150M per year
Eugia expects to maintain a global revenue run rate of $150 million per year, with US contributing $100-$110 million.
Missed
Current-quarter commentary contains related risk or weakness, so the promise appears not to have been delivered yet.
heuristic_v1
Q4 FY24
Biosimilar trastuzumab US filing within 3 months
Trastuzumab biosimilar to be filed with US FDA within the next 3 months, following a successful Type 4 pre-submission meeting.
Missed
Current-quarter commentary contains related risk or weakness, so the promise appears not to have been delivered yet.
heuristic_v1